While the marker of proliferation, MKI67, was increased in tumor samples, DIPG tumor samples showed no significant upregulation of immune checkpoint markers PD-L1 (CD274) and CTLA-4 compared to matched normal tissue (Supplementary Figure S1). Here, MKI67 is linked to neoplasm.